Whether statins improve arteriovenous fistula (AVF) outcomes is still a matter of debate. Taking into consideration the existing physicochemical differences between individual drugs, this study evaluates the impact of three different statins (atorvastatin, rosuvastatin and simvastatin) on one-stage and two-stage AVF outcomes.
Methods
Using a retrospective cohort of 535 patients, we analyzed the effects of each statin on primary failure and primary patency using multivariate logistic regressions and Cox proportional hazard models.
Results
Out of the three statins analyzed, only atorvastatin improved the overall primary failure of AVF (odds ratio [OR] = 0.18, p = 0.005). Comparisons between the two AVF types demonstrated that this effect was due to a prominent reduction in primary failure of one-stage (OR = 0.03; p = 0.005), but not two-stage fistulas (OR = 0.43; p = 0.25). In contrast, primary patency of two-stage (hazards ratio [HR] = 0.51; p = 0.024), but not one-stage fistulas (HR = 0.98; p = 0.95), was improved by all statins as a group, but not by individual drugs.
Conclusions
Our results suggest that the potential benefit of statins on AVF outcomes is a drug-specific and not a class effect, and that such effect is also influenced by the type of fistula.
SchinstockCAAlbrightRCWilliamsAWet al.Outcomes of arteriovenous fistula creation after the Fistula First Initiative.Clin J Am Soc Nephrol2011;6(8):1996–2002
2.
BasharKZafarAElsheikhSet al.Predictive parameters of arteriovenous fistula functional maturation in a population of patients with end-stage renal disease.PLoS ONE2015;10(3):e0119958
3.
PisoniRBarker-FinkelJAlloMStatin therapy is not associated with improved vascular access outcomes.Clin J Am Soc Nephrol2010;5(8):1447–1450
4.
BeathardGAArnoldPJacksonJLitchfieldTPhysician Operators Forum of RMS Lifeline.Aggressive treatment of early fistula failure. Kidney Int2003;64(4):1487–1494
5.
BavryAAMoodGRKumbhaniDJBorekPPAskariATBhattDLLong-term benefit of statin therapy initiated during hospitalization for an acute coronary syndrome: a systematic review of randomized trials.Am J Cardiovasc Drugs2007;7(2):135–141
6.
LipinskiMJCauthenCABiondi-ZoccaiGGet al.Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure.Am J Cardiol2009;104(12):1708–1716
7.
Di SciascioGPattiGPasceriVGaspardoneAColonnaGMontinaroAEfficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial.J Am Coll Cardiol2009;54(6):558–565
8.
LiakopoulosOJChoiYHHaldenwangPLet al.Impact of preoperative statin therapy on adverse postoperative outcomes in patients undergoing cardiac surgery: a meta-analysis of over 30,000 patients.Eur Heart J2008;29(12):1548–1559
9.
SchanzerAHeveloneNOwensCDBeckmanJABelkinMConteMSStatins are independently associated with reduced mortality in patients undergoing infrainguinal bypass graft surgery for critical limb ischemia.J Vasc Surg2008;47(4):774–781
10.
FeeneyJMBurnsKStaffIet al.Prehospital HMG Co-A reductase inhibitor use and reduced mortality in ruptured abdominal aortic aneurysm.J Am Coll Surg2009;209(1):41–46
11.
MasonJCStatins and their role in vascular protection.Clin Sci (Lond)2003;105(3):251–266
12.
BlumAShamburekRThe pleiotropic effects of statins on endothelial function, vascular inflammation, immunomodulation and thrombogenesis.Atherosclerosis2009;203(2):325–330
13.
Weitz-SchmidtGWelzenbachKBrinkmannVet al.Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site.Nat Med2001;7(6):687–692
14.
YoshidaMSawadaTIshiiHet al.Hmg-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: involvement of Rho GTPase-dependent mechanism.Arterioscler Thromb Vasc Biol2001;21(7):1165–1171
15.
CorpatauxJMNaikJPorterKELondonNJThe effect of six different statins on the proliferation, migration, and invasion of human smooth muscle cells.J Surg Res2005;129(1):52–56
16.
ChandrasekarBMummidiSMahimainathanLet al.Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin.J Biol Chem2006;281(22):15099–15109
17.
JanardhananRYangBVohraPet al.Simvastatin reduces venous stenosis formation in a murine hemodialysis vascular access model.Kidney Int2013;84(2):338–352
18.
BirchNFillausJFlorescuMCThe effect of statin therapy on the formation of arteriovenous fistula stenoses and the rate of reoccurrence of previously treated stenoses.Hemodial Int2013;17(4):586–593
19.
YevzlinASConleyELSanchezRJYoungHNBeckerBNVascular access outcomes and medication use: a USRDS study.Semin Dial2006;19(6):535–539
20.
RighettiMFerrarioGSerbelloniPMilaniSTommasiASome old drugs improve late primary patency rate of native arteriovenous fistulas in hemodialysis patients.Ann Vasc Surg2009;23(4):491–497
21.
SchachterMChemical, pharmacokinetic and pharmacodynamic properties of statins: an update.Fundam Clin Pharmacol2005;19(1):117–125
22.
MasonRPMolecular basis of differences among statins and a comparison with antioxidant vitamins.Am J Cardiol2006;98(11 11A):34P–41P
23.
TurnerNAMidgleyLO'ReganDJPorterKEComparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion.J Cardiovasc Pharmacol2007;50(4):458–461
24.
LaufsUWassmannSHilgersSRibaudoNBöhmMNickenigGRapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men.Am J Cardiol2001;88(11):1306–1307
25.
MarchesiSLupattelliGSiepiDet al.Short-term atorvastatin treatment improves endothelial function in hypercholesterolemic women.J Cardiovasc Pharmacol2000;36(5):617–621
26.
HerringtonWEmbersonJStaplinNet al;SHARP Investigators.The effect of lowering LDL cholesterol on vascular access patency: post hoc analysis of the Study of Heart and Renal Protection. Clin J Am Soc Nephrol2014;9(5):914–919
